Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2022-08-01
2023-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of IONM Between Remimazolam and Propofol
NCT04968054
Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam
NCT04994704
ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care
NCT05340335
Effects of Remimazolam on the Intraoperative Hemodynamics in Bypass Surgery
NCT05557253
Remimazolam and Propofol on the Left Ventricular Strain During Anesthesia Induction for Non-cardiac Surgery
NCT05412914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propofol-Remimazolam
General anesthesia was induced and maintained with propofol, then switched to remimazolam after 60 minutes from incision.
Propofol
Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Remimazolam Besylate
Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Remimazolam-Propofol
General anesthesia was induced and maintained with remimazolam, then changed to propofol after 60 minutes from incision.
Propofol
Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Remimazolam Besylate
Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propofol
Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Remimazolam Besylate
Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for elective spine surgery requiring monitoring of evoked potential
* ASA physical status 1-3
Exclusion Criteria
* Uncontrolled DM (HbA1c ≥ 9%)
* Contraindications to the study drug: known allergy or hypersensitivity
* Use of rate responsive cardiac pacemaker with bioelectrical impedence
* Diagnosed neuromuscular disorder
* Pre-existing motor weakness
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Guro Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seok Kyeong Oh
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang Sik Choi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seok Kyeong Oh
Seoul, Gangnam-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022GR0051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.